Dublin, May 09, 2025 (GLOBE NEWSWIRE) — The “Dengue Vaccine Market Opportunities and Strategies to 2034” report has been added to ResearchAndMarkets.com’s offering.
This report describes and explains the dengue vaccine market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global dengue vaccine market reached a value of nearly $408.19 million in 2024, having grown at a compound annual growth rate (CAGR) of 174.86% since 2019. The market is expected to grow from $408.19 million in 2024 to $987.42 million in 2029 at a rate of 19.32%. The market is then expected to grow at a CAGR of 16.77% from 2029 and reach $2.14 billion in 2034.
The global dengue vaccine market is highly concentrated, with few players operating in the market. The top ten competitors in the market made up to 100% of the total market in 2023. Takeda Pharmaceutical Company Limited was the largest competitor with a 90.85% share of the market, followed by Sanofi SA with 9.15%.
South America was the largest region in the dengue vaccine market, accounting for 40.79% or $166.49 million of the total in 2024. It was followed by Asia Pacific, North America and then the other regions. Going forward, the fastest-growing regions in the dengue vaccine market will be Asia Pacific and Middle East where growth will be at CAGRs of 20.70% and 20.33% respectively. These will be followed by South America and Eastern Europe where the markets are expected to grow at CAGRs of 18.97% and 17.00% respectively.
The dengue vaccine market is segmented by type into live attenuated vaccine, inactivated vaccine, subunit vaccine and nucleic acid-based vaccine. The live attenuated vaccine market was the largest segment of the dengue vaccine market segmented by type, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the live attenuated vaccine segment is expected to be the fastest growing segment in the dengue vaccine market segmented by type, at a CAGR of 18.54% during 2024-2029.
The dengue vaccine market is segmented by route of administration into oral, parenteral and other routes of administration. The parenteral market was the largest segment of the dengue vaccine market segmented by route of administration, accounting for 100.00% or $408.19 million of the total in 2024. Going forward, the parenteral segment is expected to be the fastest growing segment in the dengue vaccine market segmented by route of administration, at a CAGR of 18.32% during 2024-2029.
The dengue vaccine market is segmented by end user into hospitals, clinics, government institutes, non-governmental organizations and other end-users. The hospitals market was the largest segment of the dengue vaccine market segmented by end user, accounting for 64.86% or $264.76 million of the total in 2024. Going forward, the government institutes segment is expected to be the fastest growing segment in the dengue vaccine market segmented by end user, at a CAGR of 24.24% during 2024-2029.
The top opportunities in the dengue vaccine market segmented by type will arise in the live attenuated vaccine segment, which will gain $547.04 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by route of administration will arise in the parenteral segment, which will gain $538.24 million of global annual sales by 2029. The top opportunities in the dengue vaccine market segmented by end user will arise in the hospitals segment, which will gain $353.32 million of global annual sales by 2029. The dengue vaccine market size will gain the most in Brazil at $123.96 million.
Market-trend-based strategies for the dengue vaccine market include focus on prioritizing the development of innovative diagnostic kits to facilitate early detection, improve diagnostic accuracy and enable timely treatment of dengue infections, focus on strategic investments to expand their product portfolios, enhance vaccine efficacy and improve global access and focus on embracing strategic partnerships to drive the development of advanced vaccines.
Player-adopted strategies in the dengue vaccine market include focus on expanding manufacturing capabilities through strategic partnerships. To take advantage of the opportunities, the analyst recommends the dengue vaccine companies to focus on developing innovative diagnostic kits for dengue, focus on strategic investments for vaccine development, focus on nucleic acid-based vaccines for dengue, focus on oral vaccines for dengue prevention, expand in emerging markets, continue to focus on developed markets, focus on strategic partnerships for vaccine development, provide competitively priced offerings, continue to use b2b promotions, participate in trade shows and events, focus on government institutes for vaccine development and focus on targeting growing populations for vaccine strategies.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 294 |
| Forecast Period | 2024 – 2034 |
| Estimated Market Value (USD) in 2024 | $408.2 Million |
| Forecasted Market Value (USD) by 2034 | $2140 Million |
| Compound Annual Growth Rate | 18.0% |
| Regions Covered | Global |
Major Market Trends
- Advancements in Diagnostic Kits For Early Detection of Dengue Infections
- Investment in Novel Dengue Treatment Solutions To Address Rising Global Incidence
- Strategic Partnerships Driving Innovation in the Dengue Vaccine Market
Companies Featured
- Takeda Pharmaceutical Company Limited
- Sanofi SA
- GlaxoSmithKline plc
- Merck & Co. Inc.
- Panacea Biotec Ltd.
- Codagenix Inc.
- Serum Institute of India Pvt. Ltd.
- Inovio Pharmaceuticals Inc.
- Novavax Inc.
- Medigen Vaccine Biologics Corporation
- Bharat Biotech Ltd.
- Biological E. Limited
- Sun Pharmaceutical Industries Ltd.
- BioNet-Asia Co. Ltd.
- Zhejiang Tianyuan Bio-Pharmaceutical
- Walvax Biotechnology Co., Ltd.
- Bavarian Nordic
- Pfizer Inc., Vaxess Technologies
- Viatris Inc
- Emergent BioSolutions Inc.
- Altimmune, Inc.
- Baxter International Inc
- Moderna, Inc.
- Valneva SE
- AstraZeneca
- Johnson & Johnson
- Dynavax Technologies Corporation
- Pfizer Inc.
- BioNTech SE
- Moderna Inc., Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Vabiotech
- CSL Limited
For more information about this report visit https://www.researchandmarkets.com/r/lyhs47
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
